Method for determining the risk of developing a neurological disease

Details for Australian Patent Application No. 2005214091 (hide)

Owner Abbott Healthcare Products B.V.

Inventors Nuytinck, Lieve; Vanmechelen, Eugeen

Agent Davies Collison Cave

Pub. Number AU-B-2005214091

PCT Pub. Number WO2005/080594

Priority 60/552,847 12.03.04 US; 04103052.9 29.06.04 EP; 04447050.8 24.02.04 EP

Filing date 23 February 2005

Wipo publication date 1 September 2005

Acceptance publication date 12 August 2010

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

31 August 2006 PCT application entered the National Phase

  PCT publication WO2005/080594 Priority application(s): WO2005/080594

29 July 2010 Assignment before Grant

  Innogenetics N.V. The application has been assigned to Abbott Healthcare Products B.V.

12 August 2010 Application Accepted

  Published as AU-B-2005214091

9 December 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005214092-Additional drive system by diverting a fluid flow

2005214090-Virus purification methods